11 / 27
A p r i l 2 2 - 2 3 , 2 0 1 9
A t h e n s , G r e e c e
Page 63
Archives of Clinical Microbiology
ISSN: 1989-8436
Virology and Infectious Diseases 2019
EuroSciCon Conference on
Virology and Infectious Diseases
N
ew vaccines are required in both human and veterinary medicine. Measles virus (MV) is the only human virus within
the Morbillivirus genus of the
Paramyxoviridae
. The virus can cause severe neural complications such as measles
giant cell pneumonia, acute post measles encephalitis, subacute sclerosing panencephalitis and in immunosuppressed
individuals, measles inclusion body encephalitis. The World Health Organization has set goals towards the complete
eradication of MV. However, there are potential problems following MV eradication as the closely related veterinary
members in the genus share common cell entry receptors raising the risk of zoonotic infection. MV is thought to
have evolved from the now eradicated cattle Morbillivirus, Rinderpest and to have entered the human population
during cattle domestication. Veterinary Morbilliviruses have recently jumped into new species including non-human
primates. This highlights the possibility of zoonosis and the potential consequences of complete withdrawal of MV
vaccination (which gives some cross protection to other morbilliviruses) after measles eradication. The MV vaccine is
live attenuated and has very low risk of reversion but is still unlikely to be acceptable in a measles free world raising
the need for alternative approaches to human protection from veterinary Morbillivirus infection. Other vaccines for
diseases such as Respiratory syncytial virus and Nipah virus are also urgently needed. We are carrying out research
into recombinant vaccines using virus vector systems which can be used in both humans and animals but do not cause
disease themselves and can be delivered mucosally. These vectors can incorporate various foreign genes to protect
against viruses or other pathogens.
L.Cosby@qub.ac.ukThe need for new virus vaccines in human and
veterinary medicine with novel approaches to
design and validation
Cosby SL
1,2
, Power UP
1
, Touzelet, O
1
, de Oliveira, A
1
, Lemon K
2
Duffy, C
2
and McMenamyM
2
1
School of Medicine Dentistry and Biomedical Sciences-Queen’s University Belfast, UK
2
Agri-Food and Biosciences Institute, UK
Arch Clin Microbiol 2019, Volume:10
DOI: 10.4172/1989-8436-C1-018